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Psoriasis is a skin disorder characterized by hyperpro-
li£eration of epidermal keratinocytes. 1a,25-Dihy-
droxyvitarnin 0 3 (la,25(OHh03) and its analogs 
have been shown to inhibit keratinocyte prolifera-
tion ill vitro and to be therapeutically effective for 
the treatment of psoriasis. Some patients with psori-
asis, however, do not have a favorable response to 
1a,25(OH)203 therapy. To evaluate the differential 
responsiveness to 1a,25(OHhD3 treatment, we exalU-
ined the expression of vitamin D receptor mRNA in 
psoriatic lesions by reverse transcription-polymerase 
chain reaction using glyceraldehyde-3-phosphate de-
hydrogenase as an internal control. In this double-
blind clinical trial, we recruited 18 patients who 
received topical treatment of 1a,25(OH)zD3 (15 I-tg/g 
P soriaSis. i.S a com ..m o n skin d. isorder that.is ch ara~terized by increased numbers of undifferentiated epidermal keratinocytes and infiltration T lymphocytes and mono-cytes (Baadsgaard e/ ai, 1990). The uncont ro llcd growth of kcratinocytes in psorias is could be induced by cyto-
kines secreted fi'om epidermal immune ccll s. l a,25-Dihydroxyv i-
tanUn D , (1 a,25 (OH) 2D, ) and its ana log ca lcipotricne (Bristol-
Myers Squ ibb, Buffalo , NY) havc becn tested and provcn to be 
effective agents for treating psoriasis (Smith el ai , 1988; Holick, 
1989 , 1993; Kragballe, 1989; Kragballc et ai, 1991; Bourke el ai, 
1993; Langner el ai, 1993). A dual fun ctional ro lc for 1 a ,25(OH)2D , 
has been proposed in treating psoriasis (Kragballe, 1989). It was 
suggested that :I a,25(OI-I) 2D 3 excrts antiprolifcr<ltive activity dircctly 
on psoliatic keratinocytes and induces its tcrminal differentiation 
(Smith et ai, :I 986; Matsumoto el ai, 1990; Pillai , 1991 ; Matsumoto el ai, 
1991; Bikle c/ ai, 1993). In addition, l a,25 (OH)2D3 is a potent 
im.munoregulatory agcnt (Tsoukas ('I (/1, 1984, 1989; Reichel el ai, 
1987; Tober cl ai, J 988) and several cytokines that 1 a,25(OH)2D 3 
modulates [i.e., interleukin-1 {3, interlcukin-6, interferon-y (IFNy), 
and granulocyte macrophage-colony-stimulating f:.JCtor (GM-C SF)] 
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Vaseline) or placebo on separate psoriatic lesions for 
8 weeks. In patients who showed >90% clinical im-
proven'lent of their psoriatic lesions treated with 
1a,25(OH)2D3 (n = 9), an increase of 130 ± 37% in 
vitaluin D receptor mRNA level was observed in 
1a,25(OH)zDr treated lesions when compared with 
the corresponding placebo controls. There was no 
increase in vitan'lin D receptor mRNA level in the 
lesions treated with this drug in patients who did not 
respond to the treatment. These data suggest that the 
antiproliferative activity of 1a,25(OH)2D3 is closely as-
sociated with the expression of its cognate receptor. Key 
IVOl'ds: vitamin D receptOl·/1 a,2S -dUlydvo;\:j'vitamill DJ/pso-
riasis/skill/kemti1tocyte. ] lI",est Dc,.mato/ 106:637-641, 
1996 
have been shown to stimulate keratinocyte proliferation (Grossman CI 
al. 1989; Krueger el ai, 1990; Vollmer el ai, 1994; Bata-Csorgo, 1995). 
Thus, 1 a,25 (OHhD, may also inhibit kcratinocyte proliferation indi-
rcctly by 10wcl;ng tlle levels of cytokines secreted from epiden1lal 
immune cells. 
The efFects of 1 a,25(OI-l) ~D3 arc m ediated through its cognate 
receptor, vitamin D receptor (VDR) (Darwish and DeLuca, 1993) . 
VDR. is a liga nd-dependent, nuclear-transa ctin g fa ctor that confers 
transcriptio nal regulation by binding to the promotcr regions of 
ta rgct gen es (C'Hlberg e/ ai, 1993). It has been shown that the 
in tracc llulnr Ic vel of VD n.... protein corre lates with the cellul ar 
rcsponsiveness to la,25(OI-lLD3 (K...;shnan and Feldman, 1992; 
Z hao and Feldman , 1993). The homologous up-regulation ofVDR. 
is most like ly at thc post-transla tiona l leve l (Wiese el ai, 1992; 
Darwish and DeLuca, 1993) . VDR protcin is stabiJized aga.inst 
degradation by binding to its ligand (Wiese el ai, 1992) . The 
h e terologous up-regulation of VDR by growth factors is demon-
strated at both mRNA and protein levels (Krislman and Fc ldman , 
1991, 1992; Krishnan CI ai , 1995). In addition, thc 1 a,25(OH)2D , -
dependent gene expression might be affected by the he terogeneity 
in VDR genotypes (Morrison ef al. 1992. 1994) . 
W e (MacLaughlin CI ai , 1985) and oth ers:j: have previously 
o bscrved that dcrmal fib roblasts dcrived from involved psoriatic 
les io ll s showed a partial rcsistance to la,25(OH)2D 3-mediated 
j: Krueger GG, Jorgenscn C M: Express ion of abnormal growth ph<!no-
type ill ti broblast from patiellts with psoriasis. Sor TIII'est Dcrll/nwl 90:578 . 
199 1 (AbstL) 
0022-202X/96 / S I 0.50 • Copyright 1996 by The Socicty for Investigarive Dermatology, Inc . 
637 
638 C HEN fIT A L. 
.inhibiti on of cell growth compared with normal and uninvolved 
cultures . O ur finding was corroborated by Abe et 111 (1989), who 
found that epidermal keratinocytes derived frol11 involved psoriatic 
lesion s exhibi ted resistance to 10',25(OH)2D 3. Evaluation of the 
cl inical efficacy of 1 C/ ,2S(OH),D3 and calcipotriene on psoriasis 
showed that w hile active vitam.in D compounds are useful in 
t1·eati.ng psoriasis, not a ll patie nts respond to this therapy (Smith eI 
111, 1988; Holick, 1989, 1993; Kragballe , 1989; Kragball e Clll l, 1991; 
Bourke et 111,1993; Langner ct ai, 1993). In this study, we compared 
the VDR I11RNA concentrations in skin biopsies obtained from 
patients who did or did not respond t.o 10' ,25(OH)'03 treatmcnt. 
We found that clinical respon siven ess to 10',25(OHhD3 treatment 
correlated with th e accllmubtion of VDR mRNA in psoriati c 
lesion treated with 10',25(OH),D3. 
MATERIALS AND METI-IOOS 
Study Design Patients were admitted to the Genera l C linical Research 
Center, Hoston University Medica l Center. Informed consent was obtained 
frol11 each patient who voluntari ly participated in this double-blind, right/ 
left side comparison, clinica l trial. The thickness, scaling, and erythel11tl of 
psoriatic lesions were eva luated oil admission and "t the end of study 
according to a fonr-point improvement scale as described (Smith CI nl. ·1988; 
Kragballe, .1(89). Patients were instructed to apply topio\lIy one grain 
Vaselinc (Chesebrough Pond's USA, C l.inton, C T) containing 15 (.I.g of 
1 «,25 (01-1)20 3 to a lesion area (50 cm2) evel·y night "t bedtillle. T he 
contralateral site received Vaseline only (placebo control). After 8 weeks of 
treatment, 4 -mnl punch skin biopsies were obtained /1-0111 p/"cebo- "nd 
1 a .25(OH),D,-treatcd lesions. 
Of the total I B patients recruited to the present study. nine patients who 
showed > 90'~1 inlproVClllcnt in sc:rling, c rythCl11:I, and plaque thi ckness 
after 8-week treatment of ·1 a,25(OH)20 , were classified as responders to 
the therapy. T he other njne patients who did not show sign ificant decrease 
ill the thickness , scaling, ilnd erythema of involved lesions were classified as 
l1 onrcspolldcrs. 
RT -peR Skin biopsies were iJnl1lcrscd in liquid nitrogen inllTIcdiatc ly 
after surgical rCllloval and sto red at - 80°C until ana lysis. RNA was 
extracted frolll the biopsy with R.NA zol (13iotecx. Houston, TX) (Chom-
czynski and Sacchi , 1987). Tota l RNA (1 (.I.g) was added to the reverse 
transcription (RT) reaction (20 (.1.1) which consisted of 1. X pol ymerase chain 
reaction (PCR) buffer (10 mM Tris-I-ICI. pH 8.3, 50 111M KC /), 5 111M 
MgC/2' 20 units of RNasin, 50 units of M-MLV reVerse transcript"se, 2.5 
(.I.M random hexamer and ·1 111M each of dATI' , dGTP. dTIP, and dCT!' 
(Perkin Elmer Cetus, Norwa lk, CT). The rc"ction was carried out at room 
temperature fo r 1 0 l11in , then at 42°C for 60 lIIin . I'lNA waS omitted in the 
negative control reaction. 
T he sequence of the upstre"m primer for VDR. was 5'-ACTTCCCTGC-
CTGACCCTGG-3' (nucleotides 22-41); and the dowllStream primer was: 
5'-AGGTCTTATGGTGGGCGTCC-3' (nucleotides 428-409) (Sahota cl 
III, 199 ·') . For g/ycera /dehyde-3-phosphate dehydrogenase (GAPOH), the 
upstream primer sequence was 5' -TCCCATCACCATCTTCCA-3 ' (n ucle-
otides 276-293); and the downstream primer was 5'-GTCCACCACCCT-
GTTGCT-3' (n ucleotides I038- I021) (Sahota cl III , 1991). The I'CR 
products were 406 and 762 bp [or VDR. and GAPDH, respectively. T he 
upstream and downstream primers of VOR and GAPOH wcre located in 
the different exollS of their respective genes (Hughes el (01 , 1998; Ereolan cl 
nl.1 988) . 
PCR reaction (20 (.1./) conta ined 1 X peR buffer, 2 111M MgC/2 • 50 (.I.M 
""ch of dATI', dGTP, dTTP, and dCTP, I ,...,Ci of rj 2 PJdCTP, 0.2 /-LM of 
each primer for Von.. and GA POH, 0.5 unils ofTaq po/ymeGlSe, and' (.1.1 
ofl<.T rcaction. The PCR. mixture was then one-third se rial-diluted three to 
five times for each 5:1I11p/e. AmplifIcation of PCn.. products was performed 
in a Gene"mp PCR 9600 (Perkin Elmer Cetus, Norwalk, CT). Cycljng 
p"ral1lcters were 1 cycle of 94°C , 4· l11in; fo llowed by 30 cycles of 94°C, 15 
s; 60°C. ·15 s; and 72°C, 45 s. This was ensued by an additional e"tension 
phase of 72°C, 10 min. In the negative control tubes, either the first strand 
cON A or the Tag polymerase was absent. We have examined severa l PCR 
panl1l1ctcrs and found that the conce ntration of MgCI2. the annealing 
tcmperatllre , and the number of cycles described above wcre optimums fo r 
PCR ,ullp/i fication of VOR (data not shown) . 
The PC I'l products of VOn.. and GAPDI-I were sep"rated in a 2'Y;, 
NuSieve/1'Y;, agarose ge l (FMC Iliol'rodllcts , Rockland, ME) running 
parallel with the IOO-bp ladder (GIBCO, Ga ithersb urg. MO). Gel was 
rinscd, dried, and e"posed to a I-[yperfi /rn-M P (Amcrsham. Arlington Hts , 
IL) at - 80°C. The band in tens ities were quantifIed by densitomctric 
scanning (Mo/ecular Dynam ic, Su nnyva le, CAl. Preliminary studies showed 
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that the band intensities of PC R products we re increased linea rl y with 
increasing cxposure time 1]-0111 5 to 17 h suggesting film sens itivity was not 
c0 l11prOJlli scd . In initial c XpCrill1cnts. pe lt produc ts were South e rn trans-
fen·ed to membnll1cs alld hyb ridi zed with an interna l oligonucleotide probe 
for VDR-PC K fi·a gment (Oncogene Science Inc. , Cambridge, MA) . 
RESULTS 
A 406-bp VDR cDNA Is Amplified by peR Total .RNA 
from primary c ultures of human keratinocytcs treated with 10- 7 M 
1 0',25(OH)2D , for 24 h as described (Chcn e/ ai, 1994) was used as 
a conven ie nt source of IWA to se t up the PCR conditions. Usin g 
first strand cDNA re verse transC1"ibed fi·oL11 the total RNA of 
kerarinocytes, we observed two PCR products w ith primers de-
signed for VnR (Fig 1 , top lift pal/e1). T he es timated size of the fast 
migl·ating band WaS 406 bp, while the other was 6S0 bp. Th e 
expected size of PCR product is 406 bp as determined (i·om rh e 
human vitamin D receptor (hVDR) cD NA sequen ce (B aker cf 111 , 
1988). By increasing the a.nnealing temperature to 6S oC, o nly the 
406- bp band, but not the 650-bp band, was visible with ethidium 
bromide sta inin g. This su ggested an incomplete match of VDR 
prime rs for the 650-bp PCR product. In additio n , the 406-bp 
(i·agl11cnt WaS cleaved into 244 and 162 bp by X II/It.! as indicated 
fr0111 the hVDR cDNA sequence (42). The X liiI/I digestion was 
incomplete for PCR products preformed at annealing tempenltllre 
at S5 and 60°C (Fig 1 , lop right pill/el). 
These peR products were Southern-transferred and probed with 
an internal o ligon ucleotide of hVOR. The hybridization signal was 
observed in the 406 -bp band and absent £i·om tbe 6S0-bp band 
(Fig 1, I)()I/o/ll pal/d). An additional SOU -bp band, which was not 
observed with e thidium bromide stain , hybridized to the internal 
oligonucleotide. Its identity remains to b e dete rmined. Thus, it was 
confirmed that th e 406-bp PCR product was an authentic VOR 
fragment. Annealing temperature of ·60°C was chosen for subse-
qucnt PCR ~l11plification, since the VDR. signa l was mu ch stronger 
at this temperature compared with 65 °C. Furthermo re , both the 
650- and SOU -bp artifacts did not interfere with th e idenrification 
of th e VDR. (406 bp) and GAPDH (762 bp) PCR products. 
VDRlGAPDH Ratio Is Increased in Psoriatic Lesions 
Treated with 10',25(OH)2D3 Compared with Placebo in. the 
Responders Since GAPDH I11R.NA was used as an intern il 
co ntro l in the quantification ofVDR 1111~A level by RT-PCR, it 
was necessary to establi sh that the GAPDH mRNA level was 
not altered due to the 10:,25(OH) 20, treatment. To avoid 
inter-individual varia tion, the GAPD H mlWA le vel in the 
10',2S(OH)2Drtreated psoriatic les ions was compared to the pla-
cebo-treated lesion taken fi·om the same patient. It was found that 
the GAPDH mRNA level in 1 0',2S(OH) 2D 3-treated les ion was 92 
± IS'X, (mean ± SEM, ranged from 12 to 166%, n = 11) of that ill 
the placebo-treated lesio n (Fig 2, top pilI/d). T hese data indicated 
that the intra-individual variation in GAPDH mRNA levels was 
a randomized event and due to r.,ctor(s) oth e r than tbe 
1 a,25(OH)2D 3 treatment. It was most likely that the intra-individ-
ual variation in GAPDH mR.NA levels was att.-ibuted to the 
experimental inaccuracy in detennining RNA con centration by 
absorbance, and the efticiencies in RT and PCR reactions (tube 
effects). Furthermore, these differences werc amplified by PCR. A 
similar conclusion has been reach ed by others (Paludan et ai, 1992). 
VDR mRNA level in cach biopsy was analyzed by RT-PCR at 
least twice using GAPDH mRNA as an internal control that 
avoided the pitf.,lIs described above. T he amount ofRT added to 
a PCR reaction was adjusted to achieve a comparable GAPDI-l 
PCR signa l between placebo- and to',25(OH)2D 3-treated samples. 
Figure 2 (1Iliddle and bOl/o(1I jJllllelS), re presents a PCR. analysis of 
VDn.. mRNA con centrations in placebo- and 10:,25(OHhD3-
treated samp les in " responder. It was observed that both VDR and 
GAPDH PCR signals exhibited concentration-dependent linear 
increases, but with di.fferent slopes. This was apparcntly due to the 
difference in the concentrations of VDR and GAPDH mRNAs in 
the samples, the length of peR products, and the peR conditions. 
T h e VDR sig nals w e re consistently greater in the 10:,25(OH)2D 3-
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Figure 1. A 406-bp VDR eDNA is amplified by PCR from total RNA. Tom l RNA isolated from primary hUlllan keratinocyte cultures was converted 
to first strand eDNA and amplified by PCR. with VDR. primers. PCR. ana lyses were cond ucted at three different annea ling temperatures: 55°C, 60°C. and 
65°.C. (lOp ilji) . An aliquot of the PCR products .was digested b~' X III II I ("'I' r(~"I). Sam ples were separated on a 2% NuSievcl l 0;', agarose gel and sta.incd with 
ethidlllm bromIde . PC R. products wcre then Southern-transferred and p robed with an internal o li godeoxYllucleotidc (bOffil lll ). Numbers o n the left arc 
molecular weig ht m arkers in base pairs. 
treated lesions in each dilution examined compared with placebo , 
and the GAPDH signals were similar to each other resu lting in 
high er VDIlJGAPDH ra tios in the 1 a,25(O H)_D,-treated lesion 
compared with pla cebo contro l. Furthermore , the VDR./GA PDH 
ratios in each PCR. diluti on were similar to each other suggesting 
the consistence of the assay condition employed in this study. 
VDR/GAPD H ratios in 1 a,25(OH) 2D, - and pla cebo-trea ted 
lesions w ere co llected from a total of 18 patients: nin e responders 
and nine nonresponders. The percentage difference in VDR.I 
GAPDH ratios between 1 a,2 5(OH)2D3- and placebo-treated le-
sions in the same patient is presented in Fig 3 using the VDR.I 
GAPDH value o f the placebo-treated lesion as the denominator. In 
patients w ho showed greater than 90'X, clinical improvem ent in 
plaque thickness, eryth em a, and scale production (responder), 
[he VDR/GAPDH ratios in pso n atlc les ions treated with 
la,25(OH)2D, Were 130 ± 37'Yo greater when compared with the 
placebo- treated lesions. In contrast. the VDR/G APDH ratios 
showed no change in five out of nine nonresponders (94 -11 4% of 
placebo- treated les ions) exa mined. T he VDR/GAPDH ratios were 
actuaJly lower in 1 a,25(O H)2D 3-rreatcd les ions in the o ther fo ur 
nonrcsponders (30-50'X, of placebo-treated lesio ns). T he elevation 
of VD R./G APDH ratio in 1 a,25(O HhD,-treated lesion compared 
with placebo control in the responders was signifi cantly g reater 
than that of nonresponders (p < 0.01 , o ne-way AN OVA). 
D ISCUSS IO N 
T his stud y presents evidence that the elevation of VDR mlWA in 
psoriatic lesions treated with 1 a,25(OHhD3 correlated w ith clini-
cal improvement. In nin e out of18 par.ie llts w ho participated in this 
study, we observed a dramatic decrease in plaque th ickn ess . 
erythem a, and sca le prod uction ill I a.25(O HhD,-trcated les ion 
cornpared to " comparable lesion treated with Vasel ine. T his 
clinical response was associated with an approx.imately 2.3- fo ld 
increase in the accumulatio n of VDR mlW A in the les ion treated 
with :I a,25(O H) 2D3 compared with ti,e les ion treated with pla-
cebo, while th ere was no increase in VDR I1lRN A level in patients 
who showed resistance to topical l a,25(OH hD, treatment. 
T he increase in VDR. mR.N A leve l mig ht be due to e ith er 
enhan ced transcriptio n o r mRNA stab ilizatio n . In several stu d-
ies, the ho m o logo us up-regulati on of VDR mR.NA was not 
obse rv ed , while 25-h yd roxyvi tamin D J - 24-hydroxylase mRNA, 
a I a,25(O H hD3-depend en t gen e. showed sign ifi ca nt in crease 
(Nishimura ct III, 1994; Morgan cf " I, 1994). Weise el al (1992) 
reported that, in the absence of increased VDR mJWA level, the 
indu ction of VDR expression by 1 a,25(OHhD, is due to the 
stabilization of VDR. protein turnover. T he hetero logous up-
regulation of VDlt by some growth fa ctors, h owever, has been 
demonstrated at both mRN A and protein levels (KJ'ishnan and 
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Figure 2. VDRfGAPDH ratio in a responder is increased ill psori-
atic lesion treated with 1,2S(OHhD, compared with placebo. 
GAPDI-I mRNA levels, determined by R.T-PC R., were comparcd bctween 
psoriatic lesions treated with either 1 a .25(O I-I),D, (D) or placebo (C) (lOp). 
VOR. and GA PDI-I were coamplified by PCR. ill se rial-diluted samples 
obtained fro m Slci ll biopsies treated with " ,25(0 1-l )2D, or placebo for B 
week in a responder ("'iddle) . T he densitometric valuc of PC R. products 
from placebo- treated (GAPDH, 0; VDR., _) and 1 Cl',2S(O I-l ), D3-tJ'eated 
(GAPDI-I , 6 ; VDR, ~) lesions were presented in the bottom panel. *, a 
PCR artifact of 500 bp. 
Feldman, 1991, 1.992; Morgan el ai, 1994; KJ:ishna n el ai, 1995). 
Bata-Csorgo el al (1995) recentl y presented strong evidence t hat 
IFNI' and GM-CSF secreted from the activated T lymph ocytes are 
co-stimu lators of psoriatic keratin o cyte proli ferat io n ex 1/ ;1/0 . Th e 
prod uction of IFNI' an d GM - CSF in activated T lymphocytes is 
in hi bited by la,25(OHhDJ (Reic he l el ai, 1987; Tobe r el ai, 1987). 
Tn addition, VDn.. is expressed in ac tivated T lymphocytes ;11 1/;11'0 
(Yu el ai, 1991) and in the psodatic epiden11a l T lymphocytes 
(Mi lde el ai, 199 1) . Taken together, we spec ulate that the antipro-
li ferative e ffect of 1 a,25(OH)2D , o n keratinocy te could be m edi-
ate d by its ability to inhjbit th e prod uc tion oflFNI' and GM-CSF by 
epide rmal T lymph ocytes and th e inc rease in VDK mRNA level in 
1.a,25(OH)2Drtreated les ion mig ht be secondary to the differen-
tiation effects of 1 a,25(OH )2D , o n e pidermal im munoregulatory 
cell s in the skin . 
W e (MacLaug hlin el ai, 1985) and oth er4 have previo usly 
shown that in som e patients with p soriasis, higher concen tration of 
l a,25 (OH)zD3 was required to inhibi t the proli feration of cultured 
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Figure 3. Elevation of VDRfGAPDH ratio in 1ll',25(OH)2D J-
treated psoriatic lesions compared w ith placebo control is ob-
served in the responders, but not in the nonresponders. VO Rl 
GAPDH rotios were collec ted fi'om 0 toto l 18 patients; nine responders and 
nine no nresponders. The pcrcent<l Jjc chanJjc in V /G ralios between 
'1 a.2S(OI-l)oDr ond placebo-treated psorioti c lesiolls in the same potiellt 
W<lS calculated using; the V /G va lue of the placebo- treated lesion as the 
denomjnator. The Illean va lues (mcan ± SEM) were 230 ± 37% and 74 ± 
12% for responders and li on responders, respectively (indicated by the 
horizo /1lal lili es) . The increase ill VDR. mRNA levels in the responders was 
signi fi cantly greater than that of nonresponders (" < 0.01. one-way 
ANOVA). 
fibrob lasts d e rive d from psoriatic les io ns compared with cultured 
fib roblasts /i'om nonnal and noninvolved skin. T he same pattern of 
dec reased respons iveness to the antipro li ferative ac tiv ity of 
1 a ,25(OH)2D 3 was obse rved in c ultured hu ma n ke ratinocytes 
d e rived fi'om invol ved psoriatic lesions co mpared with no nin volved 
skjn (Abe el ai, 1989) . T his is co n sisten t w ith o ur c urre n t clinjcal 
findin g th at som e patients were res istant to 1 a, 25(OH) 2D3 treat-
m e n t . W e have now observed that responde rs cou ld be distin-
g uished from the nonrespo nders at the molecular le vel since 
nonresponders showed no e levation ofVDR mKNA (Fig 3) . Since 
o n e of the features of a psoriati c lesion is the increased number o f 
hyperproli ferative keratin o cytes and infi ltration T lymphocytes 
(Baadsgaard e/ ai, 1990) , the cell composition of skjn bio posies 
in placebo-treated les ions might have varied fi'om that of 
l a,25(OHhD)-tre<lted lesions. Suc h a shi ft in cell popu lations 
cou ld b e one of the causes of observed inc rease in VDR mRNA iu 
the responders. In additi o n , it is necessa ry to delinea te w hether the 
lev e l of VDR mRNA is re Aective of its protein level. W e are 
c UlTe ntl y ana lyz in g th e express ion of 1 a,25(OI-l)2Dr and VDR-
d e pend e n t gene, 25-hydroxyv itamin D 3-24-hydroxylase, in these 
pa tients which wi ll prov ide further insig ht o n the effi cacy of 
1a,25(OHh D ) o n responders and nonresponders . 
T he a n tiproliferative e ffec t of la,25(OH)2D J on p soriati c kcra-
tinocytes has been clearly demonstrate d , but the exact m o lecular 
m echa nism is n ot w ell unde rstood. We found that an inc rease in 
VDR ml~A le vel in the psoriati c les ion was associate d with 
impro ved clini cal response to topical 1 a,25(OH)2D3 treatment. In 
co n trast, the abse nce of in crease in VDR mP..NA was o bserved in 
patie n ts who ex hibited poor clini cal prog ress. T hese data suggested 
that the abi li ty of1 a,2 5(OH)2D ) to reg ulate ke ratinocyte growth is 
closely lin ked to the exp ression of its cognate receptor. 
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